Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 430 participants.

Also called NCT02360423

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 430 participants (planned count) (from the registry)
Sponsor
CID S.p.A. (from the registry)
Registry
  • NCT NCT02360423
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02360423. Randomized; no masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions
Intervention (Device)
CRE8 sirolimus-eluting stent
Intervention (Device)
RESOLUTE zotarolimus-eluting stent
Lead sponsor
CID S.p.A. (class: industry)

Record details

Record id
cardio:ct-nct02360423
Content hash
40dbaca1a90f6cb4d8def03706ca5e614f52a136207e2f8c9280b5c8b9976ddf